BioAge Labs (NASDAQ:BIOA) Stock Rating Lowered by Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

BIOA has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Roth Capital reiterated a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a research note on Friday, July 31st. Needham & Company LLC lowered their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. Finally, BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of BioAge Labs in a report on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Stock Performance

Shares of NASDAQ BIOA opened at $9.59 on Friday. The company has a market capitalization of $440.18 million, a P/E ratio of -4.03 and a beta of 0.94. BioAge Labs has a 12 month low of $4.58 and a 12 month high of $25.95. The stock has a 50 day moving average of $16.50 and a 200-day moving average of $17.81.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The business had revenue of $2.45 million for the quarter. Analysts predict that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares during the period. Walleye Capital LLC acquired a new position in shares of BioAge Labs during the 2nd quarter worth approximately $64,000. Marshall Wace LLP increased its holdings in shares of BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in shares of BioAge Labs in the second quarter valued at approximately $182,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.